Clarion Hotel Sign Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Precision Medicine in Cancer (E1)


Organizer(s) Richard Rosenquist, Elaine Mardis and Charles M. Perou
May 6—10, 2018
Clarion Hotel Sign • Stockholm, Sweden
Discounted Abstract Deadline: Jan 9, 2018
Abstract Deadline: Feb 6, 2018
Scholarship Deadline: Jan 9, 2018
Discounted Registration Deadline: Mar 6, 2018

Organized in collaboration with Knut and Alice Wallenberg Foundation
and Science for Life Laboratory

Sponsored by Cancer Research UK, Celgene Corporation, ImmunoGen, Inc. and Thermo Fisher Scientific Inc.

Summary of Meeting:
Thanks to next-generation sequencing, we have started to unravel the genomic landscape that contributes to the pathogenesis and/or evolution of several major cancer entities. For the majority of cancer subtypes, a quite diverse and complex mutation pattern is observed, with a limited number of frequently mutated genes accompanied by a long tail of genes with low-frequency mutations. Some of these genes have already been implied to have diagnostic, prognostic/predictive and even therapeutic impact, while most mutations still require functional validation. In parallel, large efforts have been made to design novel strategies targeting key cellular pathways and processes, which in turn has led to introduction of targeted therapy in selected entities. However, there is still a gap-of-knowledge and urgent medical need to determine how to combine the genetic information with risk-stratification and treatment algorithms in the individual patient, i.e., precision medicine. This symposium will highlight large-scale sequencing efforts carried out in different cancer types, including both solid tumors and hematological malignancies, which have paved the way for the incorporation of next-generation sequencing-based approaches into routine clinical diagnostics and every-day patient care. The conference will encompass the rapidly evolving field of disease monitoring by ultra-sensitive sequencing of tumor-specific mutations, as well as introduce novel approaches and other omics technologies and functional studies that will aid future efforts in precision medicine. Finally, successful examples of how genomic findings have spurred development of targeted therapies will be presented. In summary, the symposium will bring together basic scientists, translational researchers and clinicians to meet and discuss concerted action toward precision medicine in cancer.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, May 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, May 10 with a closing plenary session from 17:00 to 19:15, followed by a social hour and entertainment. We recommend return travel on Friday, May 11 in order to fully experience the meeting.

SUNDAY, MAY 6

4:00—8:00 PM
Arrival and Registration

Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Foyer

MONDAY, MAY 7

8:00—8:30 AM
Poster Setup

B 3
8:30 AM—5:00 PM
Poster Viewing

B 3
8:30—9:30 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Richard Rosenquist, Karolinska Institutet, Sweden

* Elaine R. Mardis, Nationwide Children's Hospital, USA

* Charles M. Perou, University of North Carolina at Chapel Hill, USA
Charting the Cancer Genome Landscape: Lessons, Opportunities and Challenges

9:30 AM—12:15 PM
Clinical Genomics in Solid Tumors
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Elaine R. Mardis, Nationwide Children's Hospital, USA

Serena Nik-Zainal, University of Cambridge, UK
Landscape of Somatic Mutations in Breast Cancer: Clinical Implications

Coffee Break

Dan Robinson, University of Michigan, USA
Integrative Clinical Genomics of Advanced Cancer

Charles Swanton, Francis Crick Institute, UK
Cancer Evolution and Immune Escape: TRACERx

12:15—12:45 PM
Lunch

B3/Atrium
12:15—2:30 PM
Poster Session 1

B 3
2:30—4:30 PM
Workshop 1: Deciphering Cancer by Next-Generation Sequencing

B 1-2
* Lillian Siu, Princess Margaret Hospital, Canada

Emelie Berglund, KTH-Royal Institute of Technology, Sweden
Spatial Transcriptomics Analysis of Castration-Resistant Prostate Cancer

Mark A. Rubin, University of Bern, Switzerland
Swiss Oncology and Cancer Immunology Breakthrough Platform (SOCIBP) for Precision Oncology

Katie Campbell, Washington University in St. Louis, USA
Comprehensive Genomics Elucidate Class I-Specific Responses due to Pembrolizumab in Treatment-Naive HNSCC

Bojan Losic, Icahn School of Medicine at Sinai, USA
Immuno-Genomic View of Intra-Tumoral Heterogeneity in Liver Cancer

Alex J. Gooding, Case Western Reserve University, USA
Novel lncRNA BORG Predicts for Metastatic Relapse and Chemoresistance in Triple-Negative Breast Cancer

Christian Brueffer, Lund University, Sweden
RNA-seq-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers in the Population-Based Multicenter SCAN-B Study

Noam Auslander, University of Maryland, USA
Robust Prediction of Therapeutic Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma

4:30—5:00 PM
Coffee Available

Foyer
5:00—7:00 PM
Precision Diagnostics in Solid Tumors
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Charles M. Perou, University of North Carolina at Chapel Hill, USA

Michael F. Berger, Memorial Sloan Kettering Cancer Center, USA
Integrated Genomic Assays for Precision Cancer Diagnostics

Lillian Siu, Princess Margaret Hospital, Canada
A Decade of Precision Medicine: Reality or Myth?

Matthew J. Ellis, Baylor College of Medicine, USA
Integrated Proteogenomics for Biomarker Discovery in Breast Cancer

7:00 PM
On Own for Dinner


TUESDAY, MAY 8

8:30—9:30 AM
Keynote Address
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Richard Rosenquist, Karolinska Institutet, Sweden

Elaine R. Mardis, Nationwide Children's Hospital, USA
Clinical Cancer Genomics in the Diagnosis of Pediatric CNS Tumors

9:30 AM—12:15 PM
Clinical Genomics in Hematological Malignancies
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA

Charles G. Mullighan, St. Jude Children's Research Hospital, USA
Advances in Genetics and Therapy in Pediatric Acute Lymphoblastic Leukemia

Coffee Break

Richard Rosenquist, Karolinska Institutet, Sweden
The Molecular Landscape of Chronic Lymphocytic Leukemia: Prognostic and Therapeutic Implications

Riccardo Dalla-Favera, Columbia University, USA
Genomics of Diffuse Large B Cell Lymphoma

Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center, USA
Genomic Drivers and Prognosis in Acute Myeloid Leukemia

12:15—5:00 PM
On Own for Lunch

12:15—1:00 PM
Poster Setup

B 3
1:00—10:00 PM
Poster Viewing

B 3
2:30—4:30 PM
Workshop 2: Circulating Cell-Free Nucleic Acid Sequencing and Detection of Minimal Residual Disease

B 1-2
* Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center, USA

Adrian V. Lee, University of Pittsburgh, USA
Targeted Mutation Detection from Fingerstick Capillary Blood using a Breast Cancer-Specific Panel MammaSeq

Celine Everaert, Ghent University, Belgium
Pan-Cancer Identification of Noncoding RNAs with Biomarker Potential in Plasma

Laura W. Dillon, NHLBI, National Institutes of Health, USA
Targeted RNA-Sequencing for the Quantification of Measurable Residual Disease in Acute Myeloid Leukemia

Louise Pettersson, Lund University, Sweden
Monitoring Leukemic Mutations Using Ultrasensitive IBSAFE Digital Droplet Analysis Predicts Relapse of Acute Myeloid Leukemia

Renate Slind Olsen, County Hospital Ryhov, Sweden
Circulating Inflammatory Factors Associated with Worse Long-Term Prognosis in Colorectal Cancer

Jennifer C. Jones, NCI, National Institutes of Health, USA
Development of an Exosome Analysis Pipeline for Precision Oncology

Johan Lindberg, Karolinska Institutet, Sweden
Cell-Free DNA Profiling of Metastatic Prostate Cancer Reveals Microsatellite Instability, Structural Rearrangements and Clonal Hematopoiesis

4:30—5:00 PM
Coffee Available

Foyer
5:00—7:00 PM
Precision Diagnostics in Hematological Malignancies
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Richard Rosenquist, Karolinska Institutet, Sweden

Maria Luisa Sulis, Columbia University Medical Center, USA
Clinical Implementation of Sequencing in Pediatric Hematology-Oncology Practice

Yanara Marincevic-Zuniga, Uppsala University, Sweden
Short Talk: DNA Methylation Classification Combined with RNA-Sequencing for Subtype Discovery in Pediatric Acute Lymphoblastic Leukemia

Mei Wang, Karolinska Institutet, China
Short Talk: RNA Sequencing-Based Prognostic Score Outperforms Conventional Prognostic Scores in Acute Myeloid Leukemia (AML)

Sylvain Mareschal, Karolinska Institutet, Sweden
Short Talk: Next-Generation Karyotyping in Acute Myeloid Leukemia

Jing Xu, German Cancer Research Center, Germany
Short Talk: Signaling Pathway Profiling in Multiple Myeloma

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

B3/Atrium
7:30—10:00 PM
Poster Session 2

B 3

WEDNESDAY, MAY 9

8:30—11:45 AM
Disease Monitoring in Cancer Patients
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Adrian V. Lee, University of Pittsburgh, USA

Catherine Alix-Panabières, University Medical Centre, France
Functional Analyses of CTCs in Cancer Patients

Alberto Bardelli, University of Torino, Italy
Cancer Evolution as a Therapeutic Target

Coffee Break

Eva Hellström-Lindberg, Karolinska Institutet, Sweden
High-Throughput Mutational Screening Improves Risk Stratification in Myelodysplastic Syndromes

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Intraclonal Dynamics in Chronic Lymphocytic Leukemia

Suresh K. Alahari, Louisiana State University Health Sciences Center, USA
Short Talk: Utilization of MicroRNAs in the Era of Personalized Medicine

Shumaila Sayyab, Uppsala University, Sweden
Short Talk: Clonal Evolution of Acute Lymphoblastic Leukemia Cells from Diagnosis to Relapse

11:45 AM—5:00 PM
On Own for Lunch

11:45 AM—1:00 PM
Poster Setup

B 3
1:00—10:00 PM
Poster Viewing

B 3
12:00—2:15 PM
SciLifeLab Lunch Seminar: Cutting-Edge Technologies in Precision Cancer Medicine (Must Register in Advance)
Register here to secure your lunch. There will also be an opportunity to register for the seminar on site at Clarion Hotel Sign, however we will not be able to offer you lunch.
More information about the program and registration: https://www.scilifelab.se/scilifelab-lunch-seminar-cutting-edge-technologies-in-precision-cancer-medicine

C12
2:15—3:30 PM
Mingle with SciLifeLab

4:30—5:00 PM
Coffee Available

Foyer
5:00—7:00 PM
Novel Approaches in Cancer Genomics
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Matthew J. Ellis, Baylor College of Medicine, USA

David T. Miyamoto, Massachusetts General Hospital, USA
Molecular Characterization of Circulating Tumor Cells for Precision Cancer Medicine

Olli Kallioniemi, Science for Life Laboratory, Sweden
Precision Systems Medicine to Tailor Cancer Treatments

Jeroen Roose, University of California, San Francisco, USA
Short Talk: Predicting Synthetic Lethality in the Context of PI3 Kinase Inhibition with High Fidelity

Arvind Singh Mer, University of Toronto, Canada
Short Talk: Systematic Identification of Genomic Predictors for Anticancer Drug Sensitivity in Patient-Derived Xenografts

Päivi Östling, Science for Life Laboratory, Karolinska Institutet, Sweden
Short Talk: Precision Systems Medicine in Urological Tumors - Molecular Profiling and Functional Testing

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

B3/Atrium
7:30—10:00 PM
Poster Session 3

B 3

THURSDAY, MAY 10

8:30—11:30 AM
Novel Targets, Novel Therapies I
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Olli Kallioniemi, Science for Life Laboratory, Sweden

Gerald P. Linette, University of Pennsylvania, USA
Melanoma Neoantigen Discovery and Clinical Validation

Winette T. Van Der Graaf, Institute of Cancer Research, UK
Targeting the Kinome in Cancer: The Need for Return Tickets from Bench to Bedside, Exemplified by the Progress in Understanding Gastrointestinal Stromal Tumors (GIST)

Coffee Break

Kenna Rael Mills Shaw, University of Texas, MD Anderson Cancer Center, USA
Precision Cancer Medicine: Neither Silver Bullet Nor an Illusion

Thomas Helleday, Karolinska Institutet, Sweden
Targeting the DNA Damage Response in Cancer

Ron S. Gejman, Memorial Sloan Kettering Cancer Center, USA
Short Talk: The Ability of T Cell Antigens to Cause Tumor Cell Rejection Is Dependent on Tumor Cell Subclone Frequency

11:30 AM—5:00 PM
On Own for Lunch

2:30—4:30 PM
Workshop 3: Identifying Novel Targets and Therapies

B 1-2
* Laurence Zitvogel, Institut Gustave Roussy, France

Eva Marina Schmidt, Ludwig-Maximillians-Universität München, Germany
Therapeutic Targeting of Tumor Heterogeneity by Inhibition of MAPK and NOTCH Signaling in Colorectal Cancer

Alexandre Couture, Normandy University, France
New Cancer Immunotherapy Strategies Based on the Use of Artificial Antigen-Presenting Cells for Activating Potent Anti-Tumor Specific CD4+ T Lymphocytes

Catríona M. Dowling, Royal College of Surgeons in Ireland, Ireland
Discovery of a Novel Histone Deacetylase 6 Inhibitor that Kills Drug-Resistant Breast Cancer

Purusottam Mohapatra, University of Lund, Sweden
WNT5A-IL-6 Signaling as a Therapeutic Target in Melanoma

Arthur L. Shaffer III, NCI, National Institutes of Health, USA
Ibrutinib Resistance in Diffuse Large B cell Lymphoma: Evolution, Novel Dependencies and Therapeutic Options

Göran Jönsson, Lund University, Sweden
Comprehensive Genomic Analysis Predict Clinical Benefit of Adoptive T Cell Therapy in Melanoma

Yardena Samuels, Weizmann Institute of Science, Israel
UVB-Induced Genomic Alterations Dictates Anti-Tumor Immune Response against Melanoma

4:30—5:00 PM
Coffee Available

Foyer
5:00—6:45 PM
Novel Targets, Novel Therapies II
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Kenna Rael Mills Shaw, University of Texas, MD Anderson Cancer Center, USA

Renier Brentjens, Memorial Sloan Kettering Cancer Center, USA
Talk Title to be Announced

Eric Tran, Providence Cancer Institute, USA
Immunogenicity and Immunotherapeutic Targeting of Mutated Neoantigens in Human Cancer

Laurence Zitvogel, Institut Gustave Roussy, France
Resistance to Immune-Checkpoint Blockade in Cancer

6:45—7:15 PM
Closing Remarks
Meeting has ended...abstracts no longer viewable online.

B 1-2
* Jonas Bergh, Karolinska Institutet, Sweden
A Clinical Oncologist's Perspective

7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

B3/Atrium
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

B 3

FRIDAY, MAY 11

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Cancer Research UK This activity was supported by an educational grant from Celgene Corporation
ImmunoGen, Inc. Science for Life Laboratory
Thermo Fisher Scientific Inc. Knut and Alice Wallenberg Foundation

We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR)

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676